Short answer
Arcutis Biotherapeutics, Inc. (ARQT) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $105M (up 60.1% year over year) with net income of −$11M.
Q1 2026 key financials · XBRL
- Revenue
- $105M
- +60.1% YoY
- Net income
- −$11M
- +54.9% YoY
- Operating margin
- -8.6%
- EPS (diluted)
- −$0.09
- +55.0% YoY
Source: XBRL data from the Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 10-Q on SEC EDGAR. USD.
Arcutis Biotherapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $105.4M, up 65% YoY from $63.8M
- Best performer ZORYVE foam revenue $49.6M, up 64% YoY
- ZORYVE cream 0.15% revenue $21.7M, up 113% YoY
- Net loss $11.3M vs $25.1M YoY
- Cash, restricted cash and marketable securities $224.3M; debt outstanding $100.0M
Risk Factors
- No risk-factors section provided; supplied text contains Items 2–6 and signatures only
- Trading-plan disclosure: CEO potential sale of up to 325,000 shares between June 12, 2026 and June 11, 2027
- Director trading-plan disclosure: potential exercise and sale of 49,134 options plus 7,609 RSU shares
- No disclosed defaults, unregistered equity sales, or mine-safety matters in the provided text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arcutis Biotherapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.